문영철(文映喆) 교수

의학과

문영철 프로필 사진

				
  • 의학관 A동(목동) 723호
  • 02-2650-2777
  • 면담 가능시간
    • 목, 금 오후 4시-6시
연구실적
  • Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone International Journal of Hematology, 2021, v.113 no.1, 81-91
    SCIE Scopus dColl.
  • Comprehensive DNA repair gene expression analysis and its prognostic significance in acute myeloid leukemia HEMATOLOGY, 2021, v.26 no.1, 904-913
    SCIE Scopus dColl.
  • Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia The Lancet Regional Health - Western Pacific, 2021, v.10, 100126
    Scopus dColl.
  • Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia International Journal of Hematology, 2021, v.114 no.3, 355-362
    SCIE Scopus dColl.
  • Impact of depression on adherence to lenalidomide plus low-dose dexamethasone in patients with relapsed or refractory myeloma Supportive Care in Cancer, 2021, v.29 no.9, 4969-4977
    SCIE Scopus dColl.
  • Risk factors for neutropenic fever in non-Hodgkin's lymphoma patients with primary granulocyte colony-stimulating factor prophylaxis KOREAN JOURNAL OF INTERNAL MEDICINE, 2021, v.36 no.5, 1181-1189
    SCIE Scopus KCI dColl.
  • The 2020 revision of the guidelines for the management of myeloproliferative neoplasms KOREAN JOURNAL OF INTERNAL MEDICINE, 2021 , 45-62
    SCIE Scopus KCI dColl.
  • A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis ANNALS OF HEMATOLOGY, 2020, v.99 no.6, 1283-1291
    SCIE Scopus dColl.
  • Emergence of Monosomy 7 in Philadelphia-Negative Cells during MDS Development and not CML Diagnosis Proved by Serial Droplet Digital PCR Laboratory Medicine Online, 2020, v.10 no.4, 321-325
    KCI dColl.
  • Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis LEUKEMIA & LYMPHOMA, 2020, v.61 no.11, 2714-2721
    SCIE Scopus dColl.
  • Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE) BRITISH JOURNAL OF HAEMATOLOGY, 2020, v.189 no.2, 303-312
    SCIE Scopus dColl.
  • Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia JOURNAL OF CLINICAL MEDICINE, 2020, v.9 no.7, 2310
    SCIE Scopus dColl.
  • Peroxiredoxin 3 has important roles on arsenic trioxide induced apoptosis in human acute promyelocytic leukemia cell line via hyperoxidation of mitochondrial specific reactive oxygen species Molecules and Cells, 2020, v.43 no.9, 813-820
    SCIE Scopus KCI dColl.
  • Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study) American Journal of Hematology, 2020, v.95 no.4, 0
    SCIE Scopus dColl.
  • Reduced-Intensity Conditioning with Busulfan and Fludarabine for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Lymphoblastic Leukemia YONSEI MEDICAL JOURNAL, 2020, v.61 no.6, 452-459
    SCIE Scopus KCI dColl.
  • The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study) Annals of Hematology, 2020, v.99 no.2, 309-319
    SCIE Scopus dColl.
  • A Phase I/II, Open-Label, Prospective, Multicenter Study to Evaluate the Efficacy and Safety of Lower Doses of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients with Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation: The KMM103 Study Biology of Blood and Marrow Transplantation, 2019, v.25 no.7, 1312-1319
    SCIE Scopus dColl.
  • Clinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, v.19 no.10, 656-664
    SCIE dColl.
  • Clinical implication of renal dysfunction during the clinical course in patients with paroxysmal nocturnal hemoglobinuria: a longitudinal analysis ANNALS OF HEMATOLOGY, 2019, v.98 no.10, 2273-2281
    SCIE Scopus dColl.
  • Degranulated Eosinophils Contain More Fine Nerve Fibers in the Duodenal Mucosa of Patients With Functional Dyspepsia JOURNAL OF NEUROGASTROENTEROLOGY AND MOTILITY, 2019, v.25 no.2, 212-221
    SCIE Scopus KCI dColl.
  • Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy Thrombosis Research, 2019, v.183, 131-135
    SCIE Scopus dColl.
  • Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, v.34 no.5, 1125-1135
    SCIE Scopus KCI dColl.
  • Somatic mutation of HLA-DRB1*04:03 in a patient with myelodysplastic syndrome at diagnosis HLA, 2019, v.93 no.4, 216-219
    SCIE Scopus dColl.
  • Clinicopathological characteristics of hyperdiploidy with high-risk cytogenetics in multiple myeloma Annals of Laboratory Medicine, 2018, v.38 no.2, 160-164
    SCIE Scopus KCI dColl.
  • Efficacy and Safety of a New 10% Intravenous Immunoglobulin Product in Patients with Primary Immune Thrombocytopenia (ITP) JOURNAL OF KOREAN MEDICAL SCIENCE, 2018, v.33 no.19
    SCIE Scopus KCI dColl.
  • GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms ANNALS OF LABORATORY MEDICINE, 2018, v.38 no.4, 296-
    SCIE Scopus KCI dColl.
  • Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients ANNALS OF HEMATOLOGY, 2018, v.97 no.6, 955-965
    SCIE Scopus dColl.
  • Multicenter Retrospective Analysis of Clinical Characteristics, Treatment Patterns, and Outcomes in Very Elderly Patients with Diffuse Large B-Cell Lymphoma: The Korean Cancer Study Group LY16-01 CANCER RESEARCH AND TREATMENT, 2018, v.50 no.2, 590-598
    SCIE Scopus KCI dColl.
  • Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150) BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, v.24 no.5, 923-929
    SCIE Scopus dColl.
  • Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma ANNALS OF ONCOLOGY, 2018, v.29 no.1, 256-263
    SCIE Scopus dColl.
  • The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma ACTA HAEMATOLOGICA, 2018, v.140 no.3, 146-156
    SCIE Scopus dColl.
  • 진단초기 만성호산구백혈병으로 오진한 호산구증가증과 복합핵형을 나타낸 역형성큰세포림프종 LABORATORY MEDICINE ONLINE, 2018, v.8 no.2, 56~61
    KCI dColl.
  • 혈액종양 진단 시에 관찰되는 자연살해세포활성의 다양성 LABORATORY MEDICINE ONLINE, 2018, v.8 no.2, 41~51
    KCI dColl.
  • A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma ONCOTARGET, 2017, v.8 no.23, 37605-37618
    SCIE Scopus dColl.
  • Comprehensive evaluation of the revised international staging system in multiple myeloma patients treated with novel agents as a primary therapy American Journal of Hematology, 2017, v.92 no.12, 1280-1286
    SCIE Scopus dColl.
  • Improved prognostic stratification using NCCN- and GELTAMO-international prognostic index in patients with diffuse large B-cell lymphoma ONCOTARGET, 2017, v.8 no.54, 92171-92182
    SCIE Scopus dColl.
  • Lymphedema associated with primary amyloidosis: A case study Annals of Rehabilitation Medicine, 2017, v.41 no.5, 887-891
    Scopus KCI dColl.
  • Management of immune thrombocytopenia: Korean experts recommendation in 2017 Blood Research, 2017, v.52 no.4, 254-263
    Scopus KCI dColl.
  • Neutrophilic Leukemoid Reaction Associated with Malignancy Initially Suspected as Chronic Neutrophilic Leukemia Laboratory Medicine Online, 2017, v.7 no.4, 206~210
    KCI dColl.
  • Novel deletion mutation of HLA-B*40:02 gene in acquired aplastic anemia HLA, 2017, v.89 no.1, 47-51
    Scopus dColl.
  • Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia CLINICAL CANCER RESEARCH, 2017, v.23 no.23, 7180-7188
    SCIE Scopus dColl.
  • The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160) ONCOTARGET, 2017, v.8 no.45, 79517-79526
    SCIE Scopus dColl.
  • VARIABLE NATURAL KILLER CELL ACTIVITY IN HEMATOLOGIC MALIGNANCIES AT DIAGNOSIS INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, v.39, 92-92
    SCIE Scopus dColl.
  • ACQUIRED HLA-B*40:02 MUTATION LEADING TO FRAME SHIFT IN DIOPATHIC APLASTIC ANEMIA HAEMATOLOGICA, 2016, v.101, 714-714
    SCIE Scopus dColl.
  • CLINICOPATHOLOGIC CHARACTERISTICS ASSOCIATED WITH NATURAL KILLER CELL ACTIVITY BY MEASUREMENT OF INTERFERON-GAMMA IN HEMATOLOGIC MALIGNANCIES HAEMATOLOGICA, 2016, v.101, 661-661
    SCIE Scopus dColl.
  • Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients Leukemia and Lymphoma, 2016, v.57 no.2, 341-347
    SCIE Scopus dColl.
  • Highly elevated serum lactate dehydrogenase is associated with central nervous system relapse in patients with diffuse large B-cell lymphoma: Results of a multicenter prospective cohort study ONCOTARGET, 2016, v.7 no.44, 72033-72043
    SCIE Scopus dColl.
  • Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study HAEMATOLOGICA, 2016, v.101 no.6, 717-723
    SCIE Scopus dColl.
  • MITOCHONDRIAL SPECIFIC ROS HYPEROXIDATION VIA PEROXIREDOXIN III HAS IMPORTANT ROLES ON ARSENIC TRIOXIDE INDUCED APOPTOSIS IN ACUTE PROMYELOCYTIC LEUKEMIA HAEMATOLOGICA, 2016, v.101, 672-672
    SCIE Scopus dColl.
  • Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome PLOS ONE, 2016, v.11 no.11
    SCIE Scopus dColl.
  • The clinical impact of thalidomide maintenance after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma in real clinical practice of Korea ANNALS OF HEMATOLOGY, 2016, v.95 no.6, 911-919
    SCIE Scopus dColl.
  • A prospective, multicenter, observational study of long-term decitabine treatment in patients with myelodysplastic syndrome Oncotarget, 2015, v.6 no.42, 44985-44994
    SCIE Scopus dColl.
  • Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome ACTA HAEMATOLOGICA, 2015, v.134 no.1, 40-48
    SCIE Scopus dColl.
  • CLINICOPATHOLOGIC CHARACTERISTICS OF UNCLASSIFIABLE MYELOPROLIFERATIVE NEOPLASMS HAEMATOLOGICA, 2015, v.100, 756-756
    SCIE Scopus dColl.
  • Calreticulin mRNA expression and clinicopathological characteristics in acute myeloid leukemia CANCER GENETICS, 2015, v.208 no.12, 630-635
    SCIE Scopus dColl.
  • Clinical Outcomes and Prognostic Factors of Up-Front Autologous Stem Cell Transplantation in Patients with Extranodal Natural Killer/T Cell Lymphoma Biology of Blood and Marrow Transplantation, 2015, v.21 no.9, 1597-1604
    SCIE Scopus dColl.
  • Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients: 12 Months Result of Phase 3 Clinical Trial BLOOD, 2015, v.126 no.23
    SCIE Scopus dColl.
  • Efficacy and safety of micafungin versus intravenous itraconazole as empirical antifungal therapy for febrile neutropenic patients with hematological malignancies: a randomized, controlled, prospective, multicenter study Annals of Hematology, 2015, 24 NOV 2015, 1-8
    SCIE Scopus dColl.
  • Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2015, v.37 no.2, 181-189
    SCIE Scopus dColl.
  • INTERNATIONAL EXTRANODAL NK/T-CELL LYMPHOMA PROJECT: PROGNOSTIC FACTORS IN THE ERA OF NONANTHRACYCLINE-BASED TREATMENT HAEMATOLOGICA, 2015, v.100, 5-5
    SCIE Scopus dColl.
  • MUTATION ANALYSIS OF JAK2, MPL, CALR, ASXL1, TET2, IDH1, IDH2, DNMT3A, AND SF3B1 IN MYELOPROLIFERATIVE NEOPLASM HAEMATOLOGICA, 2015, v.100, 530-530
    SCIE Scopus dColl.
  • Manipulation of beta-catenin pathway to overcome endocrine resistance in breast cancer. JOURNAL OF CLINICAL ONCOLOGY, 2015, v.33 no.15
    SCIE Scopus dColl.
  • Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia Blood, 2015, v.126 no.6, 746-756
    SCIE Scopus dColl.
  • PREDICTIVE FACTORS FOR TREATMENT-FREE REMISSION IN CHRONIC MYELOID LEUKEMIA PATIENTS WITH IMATINIB-TREATED, UNDETECTABLE MOLECULAR RESIDUAL DISEASE: RESULTS FROM THE KID STUDY HAEMATOLOGICA, 2015, v.100, 433-434
    SCIE Scopus dColl.
  • Predictive Value of 3-Month Early Molecular Response in New Chronic Phase Chronic Myeloid Leukemia Patients Treated with Radotinib BLOOD, 2015, v.126 no.23
    SCIE Scopus dColl.
  • Submicroscopic Deletions of Immunoglobulin Heavy Chain Gene (IGH) in Precursor B Lymphoblastic Leukemia with IGH Rearrangements ANNALS OF LABORATORY MEDICINE, 2015, v.35 no.1, 128-131
    SCIE KCI Scopus dColl.
  • The prognostic impact of inflammatory factors in patients with multiple myeloma treated with thalidomide in Korea Korean Journal of Internal Medicine, 2015, v.30 no.5, 675-683
    SCIE KCI dColl.
  • Treatment outcomes of rituximab plus hyper-CVAD in korean patients with sporadic burkitt or burkitt-like lymphoma: Results of a multicenter analysis Cancer Research and Treatment, 2015, v.47 no.2, 173-181
    KCI Scopus dColl.
  • Varicella-zoster virus-specific cell-mediated immunity and herpes zoster development in multiple myeloma patients receiving bortezomib- or thalidomide-based chemotherapy Journal of Clinical Virology, 2015, v.73, 64-69
    SCIE Scopus dColl.
  • Weekly rituximab consolidation following four cycles of R-CHOP induction chemotherapy in very elderly patients with diffuse large B-cell lymphoma: Consortium for improving survival of lymphoma study (CISL) EUROPEAN JOURNAL OF HAEMATOLOGY, 2015, v.94 no.6, 504-510
    SCIE Scopus dColl.
  • Changes in osteoblastic activity in patient who received bortezomib as second line treatment for plasma cell myeloma: A prospective multicenter study BioMed Research International, 2014
    Scopus dColl.
  • Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study Annals of Hematology, 2014, v.93 no.8, 1353-1361
    SCIE Scopus dColl.
  • Clinical Factors Associated with Response or Survival after Chemotherapy in Patients with Waldenstrom Macroglobulinemia in Korea BIOMED RESEARCH INTERNATIONAL, 2014
    SCIE dColl.
  • ETV6/RUNX1 Rearrangement Identified by RT-PCR without Evidence on FISH ACTA HAEMATOLOGICA, 2014, v.132 no.1, 122-124
    SCIE Scopus dColl.
  • Effect of anemia correction on left ventricular structure and filling pressure in anemic patients without overt heart disease KOREAN JOURNAL OF INTERNAL MEDICINE, 2014, v.29, 445-453
    SCIE KCI dColl.
  • Incidence of venous thromboembolism following major surgery in Korea: From the Health Insurance Review and Assessment Service database Journal of Thrombosis and Haemostasis, 2014, v.12 no.7
    SCIE Scopus dColl.
  • Lenalidomide with dexamethasone treatment for relapsed/refractory myeloma patients in Korea-experience from 110 patients ANNALS OF HEMATOLOGY, 2014, v.93 no.1, 113-121
    SCIE Scopus dColl.
  • Prevention of Venous Thromboembolism, 2nd Edition : Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.2, 164-171
    SCIE KCI Scopus dColl.
  • Success Rate and Risk Factors for Failure of Empirical Antifungal Therapy with Itraconazole in Patients with Hematological Malignancies : A Multicenter, Prospective, Open-Label, Observational Study in Korea JOURNAL OF KOREAN MEDICAL SCIENCE, 2014, v.29 no.1, 61-68
    SCIE KCI Scopus dColl.
  • The relationship between the success rate of empirical antifungal therapy with intravenous itraconazole and clinical parameters, including plasma levels of itraconazole, in immunocompromised patients receiving itraconazole oral solution as prophylaxis : a multicenter, prospective, open-label, observational study in Korea ANNALS OF HEMATOLOGY, 2014, v.93 no.1, 33-42
    SCIE Scopus dColl.
  • Topoisomerase II alpha and microtubule-associated protein-tau as a predictive marker in axillary lymph node positive breast cancer TUMORI, 2014, v.100 no.1, 80-86
    SCIE Scopus dColl.
  • Topoisomerase II alpha and microtubuleassociated protein-tau as a predictive marker in axillary lymph node positive breast cancer Tumori, 2014, v.100 no.1, 80-86
    Scopus dColl.
  • Transplant physicians' perceptions of cord blood transplantation in Korea: A questionnaire survey Blood Research, 2014, v.49 no.4, 228-233
    KCI Scopus dColl.
강의
  • 2022-1학기

    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
  • 2021-2학기

    • 혈액및종양

      • 학수번호 37624분반 01
      • 2학년 ( 3학점 , 65시간)
      • 전공필수 팀티칭, 의학과 외 수강불가, 마곡 104호, 자체시간표에 따른 운영
    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 팀티칭, 의학과 외 수강불가, 자체시간표에 따른 운영
  • 2021-1학기

    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영[일부 주차 대면수업]
  • 2020-2학기

    • 혈액및종양

      • 학수번호 37624분반 01
      • 2학년 ( 3학점 , 65시간)
      • 전공필수 팀티칭, 의학과외 수강불가, 마곡 104호, 자체시간표에 따른 운영
    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 팀티칭, 의학과 외 수강불가, 자체시간표에 따른 운영, 전 기간 대면수업(강의계획안 참조, 조별 일정에 따름)
    • 내과학실습 IV

      • 학수번호 K10104분반 01
      • 학년 ( 4학점 , 220시간)
  • 2020-1학기

    • 임상실습입문(IC,OSCE I)

      • 학수번호 37637분반 01
      • 3학년 ( 0.5학점 , 32시간)
      • 전공필수 의학과 외 수강불가, 자체시간표에 따라 운영
    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 의학과 외 수강불가, 팀티칭, 자체시간표에 따라 운영
    • 임상종합평가I

      • 학수번호 37667분반 01
      • 4학년 ( 1학점 , 24시간)
      • 전공필수 의학과 외 수강불가, 자체시간표에 따라 운영
  • 2019-2학기

    • 혈액및종양

      • 학수번호 37624분반 01
      • 2학년 ( 3학점 , 65시간)
      • 전공필수 팀티칭, 의학과외 수강불가, 마곡 104호, 자체시간표에 따른 운영
    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 팀티칭, 의학과 외 수강불가, 자체시간표에 따른 운영
    • 내과학실습 IV

      • 학수번호 K10104분반 02
      • 학년 ( 4학점 , 220시간)
  • 2019-1학기

    • 내과학실습Ⅳ

      • 학수번호 37644분반 01
      • 3학년 ( 4학점 , 220시간)
      • 전공필수 의학과 외 수강불가, 자체시간표에 따라 운영
    • 내과학실습 IV

      • 학수번호 K10104분반 02
      • 학년 ( 4학점 , 220시간)
학력

영남대학교 의학박사(의학과)